Figure 4

EPX-mAb immunohistochemistry provides a quantitatively significant strategy to distinguish acute lung injury patients that survive their hospitalization vs . those patients that did not survive. Sections from acute lung injury patients were subjected to EPX-mAbimmunohistochemistry prior to evaluation for evidence of eosinophil degranulation as described in the Materials amd Methods and the legend of Figure 3. Eosinophil degranulation scores were determined by individual investigators (n = 3) as the average numerical score resulting from the examination of 10 randomly selected high powered fields (hpf - 400x); investigators were blinded to both the clinical outcome and the scores of the fellow evaluator. The scatter plots presented represent values for each individual ALI patient stratified based on hospital survival. Patient eosinophil degranulation values are expressed as the mean of the average eosinophil degranulation score from all three evaluators. The error bars associated with each patient data point is the SEM linked with the mean value derived from each of the three evaluators. The mean for each cohort is presented as a horizontal bar. *p < 0.01